Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Japanese biopharmaceutical firm PeptiDream has partnered with Merck (MSD) to discover and develop new peptide therapeutics which could neutralise SARS-CoV-2, the novel coronavirus that causes Covid-19.
In April, PeptiDream launched a multi-pronged initiative to identify peptide candidates targeting various sites / regions of coronaviruses.
The partners intend to develop therapeutics with activity against the current coronavirus, as well as any future coronavirus outbreaks.